Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Despite Price Cuts, Dupixent Netting Bullish Sales to Become Sanofi’s New Flagship
October 12, 2020
- Kissei Out-Licenses Parkinson’s Med to Hong Kong’s Affamed
October 12, 2020
- Canagliflozin Approved in Indonesia: Mitsubishi Tanabe
October 12, 2020
- Takeda-Led Alliance Kicks Off Global PIII for COVID-19 Plasma Therapy
October 12, 2020
- Takeda, US Arrowhead Join Forces on Intractable Liver Disease Therapy
October 12, 2020
- Sumitomo Chemical, Sumitomo Dainippon Launch JV for Cell Therapy CDMO
October 12, 2020
- Maruho Taps Meiji as Copromotion Partner for Amenalief
October 9, 2020
- Towa Plans to Start Full-Scale Continuous Manufacturing in FY2024, Aiming at Whole Automated Process
October 9, 2020
- University of Tokyo, Eisai Link Arms for Research on Targeted Protein Degradation Technology
October 9, 2020
- AnGes Out-Licenses Collategene to Turkish Pharma
October 9, 2020
- Sumitomo Dainippon Rejigs Organization to Become Top CNS Player in Japan, Sets 50 Billion Yen Near-Term Goal
October 8, 2020
- Japan Ethical Drug Sales Dip 9.0% in August: Crecon
October 8, 2020
- Pfizer, Merck Biopharma to End Xalkori Copromotion in Japan
October 8, 2020
- Fujifilm to Expand Viral Vector CDMO Biz to Europe
October 8, 2020
- Hisamitsu Initiates Japan PIII of Palmar Hyperhidrosis Drug, Aims at Filing in FY2022
October 8, 2020
- 1 More Soft Bag Product Recalled Over Flawed Testing at Kyowa CritiCare
October 8, 2020
- HUYA Files Novel T-Cell Leukemia-Lymphoma Med in Japan
October 8, 2020
- Pfizer Renames Japan Subsidiaries as Mylan Deal Set to Close Soon; Upjohn Biz Now Separate
October 7, 2020
- Keytruda Top Selling Drug in September: Encise
October 7, 2020
- Eisai, 4 Research Organizations Begin Collaborative Project for COVID-19 Treatments
October 7, 2020
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…